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http://dx.doi.org/10.1016/j.jmii.2013Candida lipolytica candidemia is a rare but an emerging pathogenic yeast infection in humans.
It can gain access to the bloodstream through intravascular catheterization, especially through
central venous catheters in immunocompromised or critically ill patients during hospitaliza-
tion. In this report, we present a noncatheter-related C. lipolytica candidemia infection in
an 84-year-old man who was admitted due to acute pancreatitis. The possible pathogenesis
and management of C. lipolytica candidemia are highlighted. It was an unusual infectious
complication of acute pancreatitis. Clinicians should be aware that such an opportunistic path-
ogen can lead to invasive candidemia infection. In clinical practice, systemic antifungal ther-
apy and the removal of the potentially infected central venous catheter might be
recommended for the treatment of C. lipolytica candidemia.
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394 W.-C. Liu et al.Introduction treatment included temporary fasting, fluid resuscitation,Candida species are some of the most common causes of
bloodstream infections in hospitals.1 Incidences of candi-
demia have been increasing significantly in recent years.
The risk factors of candidemia are central venous cathe-
terization, parenteral hyperalimentation, broad-spectrum
antibiotics, and an immunocompromised status.2 Despite
Candida albicans being a major pathogen for candidemia,
non-albicans candidemia has been responsible for 36e63%
of all candidemia cases.2,3
Candida lipolytica was not included in the long list in
Hazen’s careful 1995 review of emerging yeast pathogens.4
C. lipolytica infection was first reported by Wehrspann and
Fu¨llbrandt in 1985.5 Since then, C. lipolytica candidemia
has been increasingly reported and strongly associated with
intravascular catheterization. In this case, candidemia
attributed to C. lipolytica infection occurred during the
treatment of acute pancreatitis, without a central venous
catheter, parenteral nutrition, and broad spectrum antibi-
otics. We sought to deepen our understanding of the clin-
ical characteristics and management of C. lipolytica
candidemia.Case report
An 84-year-old man presented to our emergency depart-
ment with a sudden onset of severe epigastric pain, which
radiated to the back after 1 day. Upon arrival, physical
examinations showed an oral temperature of 37.8 C and
epigastric tenderness without rebound tenderness. Results
of laboratory analysis revealed a white blood cell count of
15.4  103/mm3 (normal range: 4.5e11.0  103/mm3), C-
reactive protein of 5.32 mg/dL (normal range: <0.5 mg/
dL), amylase of 1597 U/L (normal range: 28e100 U/L), and
lipase concentration of 3000 U/L (normal range: 13e60 U/
L). A computed tomography of the abdomen revealed
diffuse swelling with surrounding fatty stranding and an
accumulation of peripancreatic fluid. The patient’sFigure 1. The trend graph of the highest daily body tem-
perature during the whole hospitalization period. Candida
lipolytica candidemia was identified on the 7th and 11th day,
respectively. The fever subsided after antifungal therapy with
micafungin.and pain control. The clinical symptoms improved gradually
and enteral feeding was started on the 5th day of his
admission.
On the 7th day of admission, he developed an unex-
pected fever. The trend of the highest daily body temper-
ature during the whole hospitalization is shown in Fig. 1. A
re-evaluation of the patient’s general condition showed no
pustules or skin lesions, no signs of phlebitis in the pe-
ripheral venous catheter, no ophthalmological abnormality,
no oral thrush or mucositis, no respiratory symptoms, no
cardiac murmur, no abdominal tenderness, and no dysuria.
Results of laboratory tests revealed a white blood cell
count of 17.7  103/mm3, C-reactive protein of 9.57 mg/
dL, and lipase concentration of 150 U/L. Two sets of blood
cultures from peripheral veins were obtained with an in-
terval of 30 minutes. Empiric antibiotics with intravenous
flomoxef (1.0 g) four times daily were administered
immediately. On the 8th day, 24 hours after the blood
cultures were taken, non-albicans Candida was discovered
by the BacT/ALERT Microbial Detection System (bio-
Me´rieux, France). An antifungal agent with intravenous
fluconazole (800 mg) loaded, followed by 400 mg daily was
initiated. The flomoxef treatment was discontinued. On the
11th day, a spiking fever developed again, accompanied by
general weakness and drowsiness. The blood culture was
repeated again, and antifungal therapy was shifted to
intravenous micafungin (100 mg) daily. Later, C. lipolytica
was identified by the VITEK 2 YST system (bioMe´rieux,
France) (bionumber: 5710124000025511, 97% probability).
The minimum inhibitory concentrations of five antifungal
agents against the C. lipolytica isolates were 1 mg/mL for
fluconazole, 0.125 mg/mL for itraconazole, 0.06 mg/mL
for voriconazole, 4 mg/mL for 5-flucytosine, and 0.5 mg/
mL for amphotericin B (ATB Fungus 3 system, bioMe´rieux,
France). On 15th and 19th day, the repeated blood cultures
were all sterile. After a 14-day course of intravenous anti-
fungal therapy, the patient was discharged uneventfully.Discussion
C. lipolytica, also known as Yarrowia lipolytica, is a strictly
aerobic and ubiquitous inhabitant in the environment, and
is capable of producing important metabolites and has an
intense secretory activity. It is widely used in the deter-
gent, food, and pharmaceutical industries. Several pro-
cesses based on C. lipolytica are classified as “Generally
Recognized As Safe” by the Food and Drug Administration.6
How such a yeast microorganism invades human hosts, even
causing severe bloodstream infections is an interesting
issue that is yet to be elucidated.
C. lipolytica candidemia occurs most frequently in
immunocompromised or critically ill patients during hospi-
talization. By reviewing relevant studies in English from
PubMed, we found that 16 cases, including ours, were re-
ported over the past decades. The age, gender, admission
diagnosis, whether the patient was neutropenic, whether
there was an infected vascular catheter, management and
outcomes are summarized in Table 1.5,7e15 Indwelling
catheter devices, especially central venous catheters, were
strongly correlated in almost all cases of C. lipolytica
Table 1 Clinical characteristics of patients with Candida lipolytica candidemia
No. Age Gender Admission diagnosis Neutropeniaa Infected
catheter
Main management Outcome Reference
1 57 y F Brain infarction No PVC Ketoconazole
Removal of vascular
catheter
Remission 5
2 54 y M Cholelithiasis No PVC Removal of vascular
catheter
Remission 7
3 1 mo M Necrotizing enterocolitis No CVC Fluconazole
Removal of vascular
catheter
Remission 8
4 2 mo M Bacterial meningitis Yes None None Remission 8
5 8 y F Acute myeloid leukemia Yes Hickman Amphotericin B Remission 8
6 14 y M Acute myeloid leukemia Yes Hickman Amphotericin B Remission 8
7 4 y M Aplastic anemia Yes CVC Fluconazole
Removal of vascular
catheter
Remission 8
8 15 y F Acute myeloid leukemia Yes CVC Removal of vascular
catheter
Remission 9
9 18 y F Acute leukemoid
leukemia
Yes CVC Amphotericin B
Removal of vascular
catheter
Remission 10
11 2 d M Intestinal obstruction No CVC Caspofungin
Removal of vascular
catheter
Remission 11
12 4 mo F Nosocomial pneumonia No CVC Caspofungin
Removal of vascular
catheter
Remission 11
10 2 y M Tubercular meningitis No CVC Amphotericin B
Removal of vascular
catheter
Remission 12
13 13 y M Acute leukemoid
leukemia
Yes CVC Fluconazole
Removal of vascular
catheter
Remission 13
14 9 y M Neuroblastoma Yes CVC Caspofungin
Antifungal-locked
therapy
Remission 14
15 61 y M Adenocarcinoma
of lung
No Port-A Micafungin
Removal of vascular
catheter
Remission 15
16 84 y M Acute pancreatitis No None Micafungin Remission Our case
a Absolute neutrophil count < 1000/mm3.
CVC Z central venous catheter; d Z days; m Z months; PVC Z peripheral venous catheter; y Z year.
Candida lipolytica candidemia 395candidemia. It could introduce the yeast pathogen into the
blood stream easily. In addition, D’Antonio et al claimed
that C. lipolytica produced large amounts of viscous slime
materials, which are responsible for its capability to adhere
to and colonize the central catheter.10 These cases were
proven directly by the catheter tip culture, indirectly by
the discharge culture from the venipuncture site or by the
blood culture obtained from the catheter. Therefore,
C. lipolytica might be considered one of the causative
agents of catheter-related candidemia.
In this report, C. lipolytica candidemia developed after
acute pancreatitis. Fungal infections manifesting as infec-
tious complications in severe acute pancreatitis have been
increasingly recognized in recent years. Kochhar et al sug-
gested that acute pancreatitis was associated with
increased gut mucosal permeability, which makes itpredisposed to septic complications. The translocation of
fungal flora from the gastrointestinal tract to extra-
intestinal sites plays an important role in the pathogen-
esis of fungal infections in acute pancreatits.16,17 We
speculated that C. lipolytica gains access to the blood-
stream from gastrointestinal tract mucosa. To confirm our
hypothesis, a further fungus survey or culture from the in-
testine was necessary theoretically, but would be imprac-
tical to perform in reality.
Proper management of C. lipolytica candidemia is still
controversial. Only two studies suggested that the removal
of the infected vascular catheter alone without intensive
antifungal therapy could resolve candidemia.7,9 Consistent
with the current guideline for the management of candi-
diasis,18 most studies suggest systemic antifungal therapy
as well as the removal of the potentially infected vascular
396 W.-C. Liu et al.catheter as the best treatment. In our case, systemic
antifungal therapy played a crucial role in treating C. lip-
olytica candidemia infection. Our results showed that most
C. lipolytica isolates are susceptible to fluconazole and
amphotericin B.10,11,14,15 However, the drugedrug interac-
tion and toxicity of azoles or polyene might lower the
tolerance and limit clinical applications. Furthermore,
in vitro susceptibility testing results could not be used to
predict in vivo response.15 Echinocandins are noncompeti-
tive inhibitors of the synthesis of 1,3-beta-D-glucan, which
is an integral component of the fungal cell wall. Based on
broad-spectrum activity against the Candida species, the
echinocandins were used extensively for invasive candidi-
asis, which was refractory to other antifungal therapy in
adults or when patients do not tolerate other antifungal
agents.18,19 Recent reports suggested that echinocandins
have good therapeutic effects on C. lipolytica candide-
mia.11,14,15 In the present case, micafungin was used as an
alternative antifungal therapy to fluconazole, which had
failed to eliminate C. lipolytica, and led to the resolution of
the candidemia effectively.
In conclusion, C. lipolytica is an opportunistic and
emerging human yeast pathogen. It can gain access to the
blood stream through intravascular catheterization and
possibly through the gastrointestinal tract in immunocom-
promised or critically ill patients during hospitalization.
Administration of echinocandins as an alternative antifungal
therapy is associated with successful treatment of C. lip-
olytica candidemia infection. Based on current evidence,
intensive antifungal therapy combined with the removal of
the potentially infected vascular catheter might be recom-
mended for the management of C. lipolytica candidemia.
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